Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | Q9HBH1 | 1/20 | 0.34 | |
| ▸ | HDAC3 | O15379 | 5/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | NMT2 | O60551 | 5/20 | 0.33 |
| ▸ | NMT1 | P30419 | 5/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18332122 | 0.92 | PLG (0.38) | PLGKLKB1PDFHDAC3HDAC1 | |
| SCHEMBL17650868 | 0.92 | HDAC3 (0.32) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL22698653 | 0.91 | SIRT2 (0.36) | PLGKLKB1SIRT1SIRT2 | |
| SCHEMBL25413079 | 0.90 | HDAC3 (0.36) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL20831162 | 0.89 | SIRT2 (0.36) | PLGKLKB1SIRT1SIRT2 | |
| SCHEMBL17651521 | 0.88 | CA1 (0.41) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL21695294 | 0.84 | HDAC3 (0.37) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL16847844 | 0.84 | OPRM1 (0.33) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL17801960 | 0.84 | ITGB1 (0.34) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL17813693 | 0.83 | RAB9A (0.36) | SIRT1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-3782654-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3191135-B1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH INC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20200255539-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. | 2020-08-13 | — | — | US | disclosed |
| US-10556966-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. | 2020-02-11 | — | — | US | disclosed |
| US-20190177429-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-10179820-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-10124069-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | GENENTECH, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20170174782-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9518118-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160096893-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179820-B2 | Anti-HER2 antibodies and immunoconjugates | ERBB2, EGFR, ERBB3 | PLG 3612/4885KLKB1 921/4885PDF 4083/4885 |
| US-20190177429-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | PLG 3612/4885KLKB1 921/4885PDF 4083/4885 |
| US-10556966-B2 | Anti-HER2 antibodies and immunoconjugates | ERBB2, EGFR, ERBB3 | PLG 3612/4885KLKB1 921/4885PDF 4083/4885 |
| US-20160096893-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | ERBB2, EGFR, ERBB3 | PLG 3612/4885KLKB1 921/4885PDF 4083/4885 |
| US-20200255539-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | PLG 3612/4885KLKB1 921/4885PDF 4083/4885 |
| US-20170174782-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | ERBB2, EGFR, ERBB3 | PLG 3612/4885KLKB1 921/4885PDF 4083/4885 |
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | PLG 3612/4885KLKB1 921/4885PDF 4083/4885 |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, LNPEP, BCR | PLG 381/4885KLKB1 845/4885PDF 259/4885 |
| US-10124069-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | DNPEP, LNPEP, BCR | PLG 381/4885KLKB1 845/4885PDF 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.